Clinical significance of platelet microparticles in autoimmune thrombocytopenias

Wenche Jy, Lawrence L. Horstman, Manuel Arce, Yeon Ahn

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Platelet microparticles (PMPs) are vesicles derived from platelet membranes that are too small (<0.5 μm) to be detected in routine platelet counting. They arise in association with platelet activation and other unknown causes. Elevated PMPs have been observed in idiopathic thrombocytopenic purpura (ITP), a disorder in which autoantibody interacts with platelets and the opsonized platelets are destroyed by macrophages. However, the clinical significance of PMP has been unknown. Using flow cytometry, we examined PMP concentrations in 62 patients with ITP and in 33 normal control subjects to assess the clinical significance of PMP in ITP. When compared with PMP levels in control subjects, PMP levels were significantly higher (p < 0.005) in patients with ITP, but considerable variation among individual patients was observed. Patients with platelet counts ≤60,000 were evaluated for correlation of PMP levels with manifestations of thrombocytopenias; patients without symptoms (free of petechiae or mucosal bleeding) are found to have significantly higher PMP levels (p < 0.05) than patients with symptoms, suggesting hemostatic protection by PMP. Additionally, we identified a group of patients with ITP who experienced neurologic complications resembling transient cerebral ischemic attacks (TIAs): recurrent episodes of dizzy spells or weakness in mild cases, and coma, seizure, or progressive dementia in advanced cases. Small cerebral infarcts were demonstrated by computed axial tomography scan or magnetic resonance imaging in spite of severe thrombocytopenias. Patients with this syndrome are often found to have higher PMP levels (p < 0.005) when compared with the group free of neurologic complications. It is concluded that PMPs play an important role in hemostasis in patients with thrombocytopenia, and that high concentrations of hemostatlcally active PMP can be thrombogenic in certain clinical settings. Quantitation and characterization of PMP is important in assessment and management of patients with thrombocytopenia.

Original languageEnglish
Pages (from-to)334-345
Number of pages12
JournalThe Journal of laboratory and clinical medicine
Volume119
Issue number4
StatePublished - Jan 1 1992

Fingerprint

Platelets
Blood Platelets
Idiopathic Thrombocytopenic Purpura
Thrombocytopenia
Nervous System
Purpura
Transient Ischemic Attack
Platelet Activation
Hemostatics
Flow cytometry
Coma
Macrophages
Hemostasis
Platelet Count
Magnetic resonance
Autoantibodies

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Clinical significance of platelet microparticles in autoimmune thrombocytopenias. / Jy, Wenche; Horstman, Lawrence L.; Arce, Manuel; Ahn, Yeon.

In: The Journal of laboratory and clinical medicine, Vol. 119, No. 4, 01.01.1992, p. 334-345.

Research output: Contribution to journalArticle

Jy, Wenche ; Horstman, Lawrence L. ; Arce, Manuel ; Ahn, Yeon. / Clinical significance of platelet microparticles in autoimmune thrombocytopenias. In: The Journal of laboratory and clinical medicine. 1992 ; Vol. 119, No. 4. pp. 334-345.
@article{c56b7ea8d6e94b48ab0b07bc0e3c7222,
title = "Clinical significance of platelet microparticles in autoimmune thrombocytopenias",
abstract = "Platelet microparticles (PMPs) are vesicles derived from platelet membranes that are too small (<0.5 μm) to be detected in routine platelet counting. They arise in association with platelet activation and other unknown causes. Elevated PMPs have been observed in idiopathic thrombocytopenic purpura (ITP), a disorder in which autoantibody interacts with platelets and the opsonized platelets are destroyed by macrophages. However, the clinical significance of PMP has been unknown. Using flow cytometry, we examined PMP concentrations in 62 patients with ITP and in 33 normal control subjects to assess the clinical significance of PMP in ITP. When compared with PMP levels in control subjects, PMP levels were significantly higher (p < 0.005) in patients with ITP, but considerable variation among individual patients was observed. Patients with platelet counts ≤60,000 were evaluated for correlation of PMP levels with manifestations of thrombocytopenias; patients without symptoms (free of petechiae or mucosal bleeding) are found to have significantly higher PMP levels (p < 0.05) than patients with symptoms, suggesting hemostatic protection by PMP. Additionally, we identified a group of patients with ITP who experienced neurologic complications resembling transient cerebral ischemic attacks (TIAs): recurrent episodes of dizzy spells or weakness in mild cases, and coma, seizure, or progressive dementia in advanced cases. Small cerebral infarcts were demonstrated by computed axial tomography scan or magnetic resonance imaging in spite of severe thrombocytopenias. Patients with this syndrome are often found to have higher PMP levels (p < 0.005) when compared with the group free of neurologic complications. It is concluded that PMPs play an important role in hemostasis in patients with thrombocytopenia, and that high concentrations of hemostatlcally active PMP can be thrombogenic in certain clinical settings. Quantitation and characterization of PMP is important in assessment and management of patients with thrombocytopenia.",
author = "Wenche Jy and Horstman, {Lawrence L.} and Manuel Arce and Yeon Ahn",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "119",
pages = "334--345",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical significance of platelet microparticles in autoimmune thrombocytopenias

AU - Jy, Wenche

AU - Horstman, Lawrence L.

AU - Arce, Manuel

AU - Ahn, Yeon

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Platelet microparticles (PMPs) are vesicles derived from platelet membranes that are too small (<0.5 μm) to be detected in routine platelet counting. They arise in association with platelet activation and other unknown causes. Elevated PMPs have been observed in idiopathic thrombocytopenic purpura (ITP), a disorder in which autoantibody interacts with platelets and the opsonized platelets are destroyed by macrophages. However, the clinical significance of PMP has been unknown. Using flow cytometry, we examined PMP concentrations in 62 patients with ITP and in 33 normal control subjects to assess the clinical significance of PMP in ITP. When compared with PMP levels in control subjects, PMP levels were significantly higher (p < 0.005) in patients with ITP, but considerable variation among individual patients was observed. Patients with platelet counts ≤60,000 were evaluated for correlation of PMP levels with manifestations of thrombocytopenias; patients without symptoms (free of petechiae or mucosal bleeding) are found to have significantly higher PMP levels (p < 0.05) than patients with symptoms, suggesting hemostatic protection by PMP. Additionally, we identified a group of patients with ITP who experienced neurologic complications resembling transient cerebral ischemic attacks (TIAs): recurrent episodes of dizzy spells or weakness in mild cases, and coma, seizure, or progressive dementia in advanced cases. Small cerebral infarcts were demonstrated by computed axial tomography scan or magnetic resonance imaging in spite of severe thrombocytopenias. Patients with this syndrome are often found to have higher PMP levels (p < 0.005) when compared with the group free of neurologic complications. It is concluded that PMPs play an important role in hemostasis in patients with thrombocytopenia, and that high concentrations of hemostatlcally active PMP can be thrombogenic in certain clinical settings. Quantitation and characterization of PMP is important in assessment and management of patients with thrombocytopenia.

AB - Platelet microparticles (PMPs) are vesicles derived from platelet membranes that are too small (<0.5 μm) to be detected in routine platelet counting. They arise in association with platelet activation and other unknown causes. Elevated PMPs have been observed in idiopathic thrombocytopenic purpura (ITP), a disorder in which autoantibody interacts with platelets and the opsonized platelets are destroyed by macrophages. However, the clinical significance of PMP has been unknown. Using flow cytometry, we examined PMP concentrations in 62 patients with ITP and in 33 normal control subjects to assess the clinical significance of PMP in ITP. When compared with PMP levels in control subjects, PMP levels were significantly higher (p < 0.005) in patients with ITP, but considerable variation among individual patients was observed. Patients with platelet counts ≤60,000 were evaluated for correlation of PMP levels with manifestations of thrombocytopenias; patients without symptoms (free of petechiae or mucosal bleeding) are found to have significantly higher PMP levels (p < 0.05) than patients with symptoms, suggesting hemostatic protection by PMP. Additionally, we identified a group of patients with ITP who experienced neurologic complications resembling transient cerebral ischemic attacks (TIAs): recurrent episodes of dizzy spells or weakness in mild cases, and coma, seizure, or progressive dementia in advanced cases. Small cerebral infarcts were demonstrated by computed axial tomography scan or magnetic resonance imaging in spite of severe thrombocytopenias. Patients with this syndrome are often found to have higher PMP levels (p < 0.005) when compared with the group free of neurologic complications. It is concluded that PMPs play an important role in hemostasis in patients with thrombocytopenia, and that high concentrations of hemostatlcally active PMP can be thrombogenic in certain clinical settings. Quantitation and characterization of PMP is important in assessment and management of patients with thrombocytopenia.

UR - http://www.scopus.com/inward/record.url?scp=0026724861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026724861&partnerID=8YFLogxK

M3 - Article

C2 - 1583382

AN - SCOPUS:0026724861

VL - 119

SP - 334

EP - 345

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 4

ER -